Why use StaphAseptic instead of a triple antibiotic?
• StaphAseptic kills 99.9% of antibiotic resistant staph (MRSA)*. Topical triple antibiotics have not been found to be effective against MRSA. • Public health experts are concerned about antibiotic resistance, a problem that can develop when antibiotics are overused. Over time, germs develop new defenses against antibiotics that once were effective against them. Bacteria reproduce quickly and pass these defenses rapidly from one generation to the next until almost all are immune to the effects of a particular antibiotic. This process appears to be happening faster than new antibiotics can be developed. • Roughly 5%-10% of people may be allergic to one or more ingredients in topical antibiotic products. * In vitro studies show that StaphAseptic kills over 99.9% of methicillin resistant staphylococcus aureus (MRSA).
Related Questions
- What is the most important information I should know about Mycitracin Triple Antibiotic (Bacitracin/Neomycin/Polymyxin B Topical)?
- What is the most important information I should know about Triple Antibiotic (Bacitracin/Neomycin/Polymyxin B Topical)?
- What are the possible side effects of Mycitracin Triple Antibiotic (Bacitracin/Neomycin/Polymyxin B Topical)?
